NORTHBROOK, IL -- (Marketwired) -- 07/02/13 -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced publication of a prospective, multicenter study that illustrates the high diagnostic accuracy and potential clinical impact of the company's FDA-cleared Verigene® Gram-Positive Blood Culture (BC-GP) Test in the peer-reviewed, open-access journal PLOS Medicine, published by the Public Library of Science.
The results reported in this manuscript, authored by leading experts in microbiology and molecular diagnostics, demonstrate the performance of the Verigene BC-GP Test in simultaneously detecting and identifying Staphylococcus aureus and 11 other gram-positive bacterial gene targets known to cause bloodstream infections and three genetic resistance determinants (the mecA, vanA, and vanB genes), directly from positive blood culture media. In addition, a retrospective analysis of turn-around time found that the Verigene BC-GP Test identified methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) species -- two especially deadly causes of bloodstream infection -- an average of 42 hours faster than reference methods.
"The study concluded that the Verigene BC-GP Test is capable of detecting the leading causes of gram-positive bacterial bloodstream infections as well as genetic markers for methicillin resistance in Staphylococcus aureus and vancomycin resistant Enterococcus directly from positive blood cultures, and has the potential to markedly reduce turn-around time for reporting," said Dr. Nathan A. Ledeboer, Associate Professor of Pathology at the Medical College of Wisconsin.
"We are very pleased these study results have been published in PLOS Medicine, an evidence-based journal that focuses on diseases that cause the greatest healthcare and economic burden worldwide," said Michael McGarrity, Nanosphere's president and chief executive officer. "These results are significant as they further validate the compelling value of the Verigene BC-GP Test in enabling rapid analysis and reporting of this time-critical, clinically actionable information to physicians. Our tests have been designed based on comprehensive market feedback to work hand-in-hand with laboratory best practices to provide physicians with the optimal set of results for clinical decision making. Furthermore, we believe the Verigene System's ability to directly detect a comprehensive panel of bacterial DNA targets without the use of PCR is ideally and uniquely suited to the challenge of accurately identifying organisms in blood culture media."
The manuscript, published under the title "Multiplex Identification of Gram-positive Bacteria and Resistance Determinants Directly from Positive Blood Culture Broths: Evaluation of an Automated Microarray-Based Nucleic Acid Test," was composed by Blake W. Buchan(1), Christine C. Ginocchio(2,3), Ryhana Manji(2), Robert Cavagnolo(4), Preeti Pancholi(5), Lettie Swyers(5), Richard B. Thomson Jr.(6), Christopher Anderson(6), Karen Kaul(6), and Nathan A. Ledeboer(1).
With an impact factor of 16, PLOS Medicine is the leading open-access medical journal, providing an influential venue for outstanding research and commentary on the major challenges to human health worldwide.
About Verigene® Gram-Positive Blood Culture Nucleic Acid Test
The Verigene® Gram-Positive Blood Culture Nucleic Acid (BC-GP) Test performed using the sample-to-result Verigene System is a qualitative, multiplexed in vitro diagnostic test for the simultaneous detection and identification of potentially pathogenic gram-positive bacteria which may cause bloodstream infection. These include the following organisms and antibiotic resistance markers:
Streptococcus anginosus group
mecA gene, conferring methicillin resistance
vanA and vanB genes, conferring vancomycin resistance
The Verigene BC-GP Test is performed directly on blood culture bottles identified as positive by a continuous monitoring blood culture system and which contain gram-positive bacteria. The Verigene BC-GP Test is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial bloodstream infections; however, it is not to be used to monitor these infections. Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, identify organisms not detected by the Verigene BC-GP Test, differentiate mixed growth, associate antimicrobial resistance marker genes to a specific organism, or for epidemiological typing.
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for multiplexed infectious disease, genetic, and ultra-sensitive protein testing. This easy-to-use platform offers laboratories a convenient, simple, and cost-effective solution for highly sensitive nucleic acid and protein testing. Nanosphere is based in Northbrook, IL.
For additional information regarding Nanosphere's infectious disease products, please contact Nanosphere at IDtesting@nanosphere.us or visit www.nanosphere.us.
1 Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America,
2 North Shore-LIJ Health System, New York, New York, United States of America,
3 Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, United States of America,
4 med fusion LLC, Lewisville, Texas, United States of America,
5 Department of Pathology, The Ohio State University Medical Center, Columbus, Ohio, United States of America,
6 Department of Pathology; NorthShore University HealthSystem, Evanston, Illinois, United States of America
Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere's ability to develop commercially viable products; (ii) Nanosphere's ability to achieve profitability; (iii) Nanosphere's ability to produce and market its products; (iv) Nanosphere's ability to obtain regulatory approval of its products; (v) Nanosphere's ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere's ability to obtain additional financing to support its operations. Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Chief Financial Officer
Director of Communications
Most Popular Stories
- Chobani Counters Competition With Expanded Lineup
- Nevada Range Showdown Draws Armed Supporters
- 'Beige Book' Federal Reserve Survey, April 2014: Full Text
- Iran Denounces U.S. Ruling to Sell Property
- Report: Iran VP Says Row Over Reactor Resolved
- NASA's Space Station Robonaut Finally Getting Legs
- Confusion, Anger as Sunken Ferry's Relatives Wait
- Fiat Chrysler to Build 3 Jeeps in China
- Ohio Couple Married 70 Years, Die 15 Hours Apart
- Hawaii is Genetically Engineered Crop Flash Point